Q-omics provides the consensus-scored NDUFV2 profile across patient tissues and cancer cell-line models. NDUFV2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFV2 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, NDUFV2 protein abundance shows 23,521 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where NDUFV2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFV2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFV2 survival associations across molecular data types. NDUFV2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFV2 RNA expression–survival associations across cancer types. High NDUFV2 expression shows unfavorable associations in UVM, SCLC, ACC, LUAD and ESCA, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFV2 RNA expression.
This table summarizes NDUFV2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFV2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFV2 shows lower tumor expression in KIRP, READ and COAD and higher tumor expression in BLCA, BRCA and LUAD. The BLCA box plot shows higher NDUFV2 RNA expression in tumor versus normal tissue (log2 FC = +0.759, t-test p = .001).
This table shows molecular features associated with NDUFV2 in patient tissues and cancer cell lines. In patient samples, NDUFV2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFV2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
